Irritable Bowel Syndrome

---

Butyrate is a short-chain fatty acid produced by beneficial gut bacteria when they ferment dietary fiber. It serves as a primary energy source for the cells lining the colon and plays an important role in maintaining gut barrier integrity, regulating immune responses, and supporting communication between the gut and the nervous system [1-3].

In people with irritable bowel syndrome (IBS), researchers have frequently observed alterations in the gut microbiome, including reductions in certain butyrate-producing bacteria. These changes may contribute to symptoms such as abdominal discomfort, bloating, altered bowel habits, and increased intestinal sensitivity. Because butyrate helps support a healthy intestinal environment, it has become an area of growing interest in IBS research [1-4].

Several studies have suggested that butyrate supplementation may help improve symptoms in some individuals with IBS. A randomized clinical study found that microencapsulated sodium butyrate reduced abdominal pain, discomfort during defecation, and urgency after several weeks of supplementation [4]. More recent research has also reported improvements in quality of life and favorable changes in the gut microbiome among IBS patients receiving sodium butyrate [5].

Researchers believe these effects may result from butyrate's ability to support intestinal barrier function, influence gut motility, and modulate signaling pathways involved in visceral hypersensitivity—the heightened pain response often observed in IBS [1-3].

IBS is increasingly recognized as a disorder involving the gut-brain axis, the bidirectional communication network connecting the gastrointestinal tract and the central nervous system. Stress, anxiety, and emotional health can influence digestive symptoms, while signals originating in the gut can affect mood and well-being.

Butyrate has emerged as an important mediator of gut-brain communication. Experimental studies suggest that it may influence neurotransmitter production, immune signaling, and neural pathways linking the gut and brain. While much of this research remains ongoing, these findings highlight the potential importance of maintaining healthy butyrate levels for overall digestive and neurological health [2,6].

Because butyrate is produced through the fermentation of dietary fiber, nutrition plays a key role in supporting its natural production. Foods rich in fermentable fibers—including oats, legumes, fruits, vegetables, and whole grains—can help nourish butyrate-producing bacteria.

Researchers are also investigating microbiome-directed approaches that support beneficial bacteria and increase butyrate production within the colon. These strategies may help promote digestive comfort and support a healthy intestinal environment, although they should not replace medical evaluation or treatment when needed [1,2].

While IBS is a complex condition with multiple contributing factors, butyrate remains one of the most promising microbiome-derived compounds being studied. Its ability to support gut barrier integrity, influence immune signaling, and participate in gut-brain communication makes it an attractive target for future nutritional and microbiome-based interventions.

Although more large-scale clinical studies are needed, current evidence suggests that supporting healthy butyrate levels may contribute to improved digestive comfort and overall gut health in some individuals with IBS.

BACK

References:

1. Dalile B, Van Oudenhove L, Vervliet B, Verbeke K. The role of short-chain fatty acids in microbiota-gut-brain communication. Nat Rev Gastroenterol Hepatol. 2019 Aug;16(8):461-478. doi: 10.1038/s41575-019-0157-3. PMID: 31123355.

2. Parada Venegas D, De la Fuente MK, Landskron G, González MJ, Quera R, Dijkstra G, Harmsen HJM, Faber KN, Hermoso MA. Short Chain Fatty Acids (SCFAs)-Mediated Gut Epithelial and Immune Regulation and Its Relevance for Inflammatory Bowel Diseases. Front Immunol. 2019 Mar 11;10:277. doi: 10.3389/fimmu.2019.00277. Erratum in: Front Immunol. 2019 Jun 28;10:1486. doi: 10.3389/fimmu.2019.01486. PMID: 30915065; PMCID: PMC6421268.

3. Peng L, Li ZR, Green RS, Holzman IR, Lin J. Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. J Nutr. 2009 Sep;139(9):1619-25. doi: 10.3945/jn.109.104638. Epub 2009 Jul 22. PMID: 19625695; PMCID: PMC2728689.

4. Banasiewicz T, Krokowicz Ł, Stojcev Z, Kaczmarek BF, Kaczmarek E, Maik J, Marciniak R, Krokowicz P, Walkowiak J, Drews M. Microencapsulated sodium butyrate reduces the frequency of abdominal pain in patients with irritable bowel syndrome. Colorectal Dis. 2013 Feb;15(2):204-9. doi: 10.1111/j.1463-1318.2012.03152.x. PMID: 22738315.

5. Facchin S, Vitulo N, Calgaro M, Buda A, Romualdi C, Pohl D, Perini B, Lorenzon G, Marinelli C, D'Incà R, Sturniolo GC, Savarino EV. Microbiota changes induced by microencapsulated sodium butyrate in patients with inflammatory bowel disease. Neurogastroenterol Motil. 2020 Oct;32(10):e13914. doi: 10.1111/nmo.13914. Epub 2020 May 31. PMID: 32476236; PMCID: PMC7583468.

6. Silva YP, Bernardi A, Frozza RL. The Role of Short-Chain Fatty Acids From Gut Microbiota in Gut-Brain Communication. Front Endocrinol (Lausanne). 2020 Jan 31;11:25. doi: 10.3389/fendo.2020.00025. PMID: 32082260; PMCID: PMC7005631.